Canada NewsWire
LAVAL, QC, June 13, 2018
LAVAL, QC, June 13, 2018 /CNW/ - Crescita Therapeutics
Inc. (TSX: CTX) (Crescita or the Company), a commercial dermatology company with a portfolio of non-prescription skincare and
prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that all
nominees listed in the Management Proxy Circular dated May 8, 2018 were elected as directors of the
Company at its 2018 Annual and Special Meeting of Shareholders held at its corporate headquarters in Laval, Québec.
The detailed results of the votes by proxy are as follows:
|
Director Nominees
|
NUMBER OF SHARES
|
PERCENTAGE OF VOTES CAST
|
|
FOR
|
WITHHELD
|
FOR
|
WITHHELD
|
|
Daniel N. Chicoine
|
7,296,633
|
723,828
|
91.0%
|
9.0%
|
|
David A. Copeland
|
7,311,455
|
709,006
|
91.2%
|
8.8%
|
|
Anthony E. Dobranowski
|
7,297,395
|
723,066
|
91.0%
|
9.0%
|
|
John C. London
|
7,295,486
|
724,975
|
91.0%
|
9.0%
|
|
Samira Sakhia
|
7,314,796
|
705,665
|
91.2%
|
8.8%
|
|
Thomas Schlader
|
7,313,531
|
706,930
|
91.2%
|
8.8%
|
About Crescita Therapeutics Inc.
Crescita (TSX:CTX) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription
skincare products for the treatment and care of skin conditions and diseases and their symptoms and prescription drug products
for the treatment of pain. Crescita owns multiple proprietary drug delivery platforms that support the development of
patented formulations that can facilitate the delivery of active drugs into or through the skin. For additional information,
please visit www.crescitatherapeutics.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/crescita-therapeutics-announces-director-election-results-of-its-annual-general-meeting-300666109.html
SOURCE Crescita Therapeutics Inc.
View original content with multimedia: http://www.newswire.ca/en/releases/archive/June2018/13/c4559.html